Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Kifissia – page 32

1 033 clinical trials in Kifissia, Greece across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Kifissia at a glance
1 033
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 033 trials in Kifissia

Open in trial search

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Study of Avacopan Safety and Effectiveness in Patients with ANCA-associated Vasculitis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Avacopan
  • Sponsor:Amgen Inc.

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Staphylococcal bacteraemia

Not yet recruiting

Safety and Efficacy of Ceftobiprole Medocaril Sodium in Children with Staphylococcus aureus Bacteremia Including Right‑Sided Infective Endocarditis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Ceftobiprole medocaril sodium
  • Sponsor:Istx LLC

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer

Not yet recruiting

A Phase 3 Trial of BL-M14D1 and Atezolizumab vs Standard Therapy in First‑Line Extensive‑Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Systimmune Inc.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Greece

The busiest research cities in the country

All 47 cities in Greece

Clinical research in Kifissia

What the registry says about research in the country

01 Oncology Research

Groundbreaking clinical trials focusing on non-small cell lung cancer and innovative treatment combinations. Studies evaluating novel therapies including immunotherapy agents and targeted treatments for various stages of cancer.

  • Advanced NSCLC Treatments
  • Breast Cancer Therapies
  • Gastrointestinal Cancer Studies

Multiple trials exploring combination therapies with chemotherapy and radiation for enhanced treatment outcomes.

02 Cardiovascular Studies

Important research in atrial fibrillation and stroke prevention, investigating new therapeutic approaches for cardiovascular conditions. Studies focusing on novel anticoagulants and heart attack treatments.

  • Stroke Prevention Therapies
  • Cardiac Rhythm Management
  • Acute Coronary Syndrome

Innovative treatments being evaluated to improve patient outcomes in emergency cardiovascular care.

03 Neurological Research

Clinical investigations targeting Alzheimer's disease and associated conditions, with a focus on managing psychosis and cognitive symptoms. Studies evaluating novel therapeutic approaches.

  • Alzheimer's Disease Treatments
  • Psychosis Management
  • Cognitive Function Studies

Dedicated research into improving quality of life for patients with neurodegenerative conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.